95.61
Zimmer Biomet Holdings Inc stock is traded at $95.61, with a volume of 3.65M.
It is up +4.61% in the last 24 hours and up +2.97% over the past month.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
See More
Previous Close:
$91.40
Open:
$90.87
24h Volume:
3.65M
Relative Volume:
1.64
Market Cap:
$18.95B
Revenue:
$8.01B
Net Income/Loss:
$807.20M
P/E Ratio:
23.66
EPS:
4.0411
Net Cash Flow:
$1.13B
1W Performance:
+8.54%
1M Performance:
+2.97%
6M Performance:
-4.41%
1Y Performance:
-3.40%
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Name
Zimmer Biomet Holdings Inc
Sector
Industry
Phone
(574) 267-6131
Address
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ZBH
Zimmer Biomet Holdings Inc
|
95.61 | 18.11B | 8.01B | 807.20M | 1.13B | 4.0411 |
|
ABT
Abbott Laboratories
|
113.59 | 195.24B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
363.70 | 138.08B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
101.08 | 130.02B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
73.47 | 110.11B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
79.33 | 44.71B | 5.88B | 1.34B | 799.60M | 2.3489 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-06-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-18-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jul-15-25 | Upgrade | Roth Capital | Neutral → Buy |
| Dec-17-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Peer Perform |
| Jul-01-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| May-21-24 | Upgrade | Argus | Hold → Buy |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-20-23 | Initiated | ROTH MKM | Neutral |
| Aug-28-23 | Upgrade | BTIG Research | Neutral → Buy |
| May-03-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Upgrade | Jefferies | Underperform → Hold |
| Mar-29-23 | Initiated | UBS | Sell |
| Mar-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Underweight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Apr-01-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Mar-02-22 | Downgrade | Loop Capital | Buy → Hold |
| Feb-08-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-08-22 | Reiterated | Citigroup | Buy |
| Feb-08-22 | Reiterated | Deutsche Bank | Hold |
| Feb-08-22 | Reiterated | JMP Securities | Mkt Outperform |
| Feb-08-22 | Reiterated | JP Morgan | Neutral |
| Feb-08-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-08-22 | Reiterated | Stifel | Buy |
| Feb-08-22 | Reiterated | Truist | Buy |
| Feb-08-22 | Reiterated | UBS | Neutral |
| Feb-08-22 | Reiterated | Wells Fargo | Underweight |
| Feb-02-22 | Downgrade | UBS | Buy → Neutral |
| Jan-19-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-10-22 | Downgrade | Mizuho | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-09-21 | Downgrade | Needham | Strong Buy → Buy |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Nov-23-21 | Downgrade | Argus | Buy → Hold |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jan-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-18-20 | Reiterated | Needham | Strong Buy |
| Oct-20-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Aug-05-20 | Reiterated | Needham | Strong Buy |
| Apr-28-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-09-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-07-20 | Reiterated | Needham | Strong Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jan-07-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-04-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-19 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-18-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-12-19 | Upgrade | Argus | Hold → Buy |
| Jul-30-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-11-19 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-24-19 | Upgrade | Needham | Buy → Strong Buy |
View All
Zimmer Biomet Holdings Inc Stock (ZBH) Latest News
Zimmer Biomet Holdings Inc (ZBH) Q4 2025 Earnings Call Highlight - GuruFocus
Zimmer Biomet (NYSE:ZBH) Beats Estimates, Lifts Russell 1000 Healthcare - Kalkine Media
Zimmer Biomet (ZBH) Is Up 6.1% After Earnings Beat And New Buyback Plan Is Announced - Yahoo Finance
Citigroup Raises Price Target for Zimmer Biomet Holdings (ZBH) | ZBH Stock News - GuruFocus
Wells Fargo Raises Zimmer Biomet Holdings (ZBH) Price Target to $98 | ZBH Stock News - GuruFocus
Wells Fargo & Company Forecasts Strong Price Appreciation for Zimmer Biomet (NYSE:ZBH) Stock - MarketBeat
UBS Adjusts Price Target on Zimmer Biomet Holdings to $89 From $86, Maintains Sell Rating - marketscreener.com
ZBH Q4 Deep Dive: U.S. Salesforce Overhaul Drives Guidance Caution Amid Product Momentum - Finviz
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q4 2025 earnings call transcript - MSN
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q4 2025 Earnings Call Transcript - Insider Monkey
Zimmer plans US salesforce reorganization - Yahoo Finance
Zimmer Biomet Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Zimmer Biomet shares climb after fourth-quarter sales and earnings growth - AlphaStreet News
Zimmer Biomet Q4 Earnings Call Highlights - Yahoo Finance
Zimmer Biomet outlines 2026 revenue growth of 1%–3% amid US sales force overhaul and innovation cycle - MSN
Zimmer Biomet earnings beat Wall Street expectations - The Journal Gazette
BTIG Reiterates Buy Rating on Zimmer Biomet (ZBH) with $112 PT | - GuruFocus
Zimmer Biomet (NYSE:ZBH) Earns Hold Rating from Needham & Company LLC - MarketBeat
BTIG Research Reiterates Buy Rating for Zimmer Biomet (NYSE:ZBH) - MarketBeat
Citigroup Raises Price Target on Zimmer Biomet to $98 From $94, Maintains Neutral Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Zimmer Biomet to $98 From $93 - marketscreener.com
Zimmer Biomet beats quarterly estimates on strong implant demand amid US sales overhaul - marketscreener.com
Zimmer Biomet reports 2025 revenue growth yet tempers 2026 outlook - Yahoo Finance
Zimmer Biomet posts Q4 beats, sets 2026 guidance - MassDevice
Zimmer Biomet (ZBH) Exceeds Q4 Expectations with Strong Orthoped - GuruFocus
Zimmer Biomet Holdings, Inc. announces an Equity Buyback for $1,500 million worth of its shares. - marketscreener.com
Tranche Update on Zimmer Biomet Holdings, Inc.'s Equity Buyback Plan announced on May 29, 2024. - marketscreener.com
Zimmer (ZBH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore
Zimmer Biomet (NYSE:ZBH) Beats Q4 CY2025 Sales Expectations - Finviz
Zimmer Biomet Q4 2025 Earnings & 2026 Financial ForecastNews and Statistics - IndexBox
Zimmer Biomet (NYSE:ZBH) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Zimmer Biomet tops Q4 expectations but strikes measured tone on 2026 guidance - MSN
Zimmer Biomet beats quarterly estimates on strong hips, knees device demand - marketscreener.com
Zimmer Biomet (NYSE:ZBH) Releases FY 2026 Earnings Guidance - MarketBeat
Zimmer Biomet (ZBH) Announces $1.5 Billion Stock Buyback Plan - GuruFocus
Zimmer Biomet (ZBH) Projects Revenue Growth for Fiscal Year 2026 - GuruFocus
Zimmer Biomet (ZBH) Reports Strong Q4 Revenue and Strategic Adva - GuruFocus
Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates - Yahoo Finance Singapore
Zimmer Biomet (ZBH) Q4 Earnings Surpass Expectations, Announces Buyback Plan - GuruFocus
Zimmer: Q4 Earnings Snapshot - kens5.com
(ZBH) Zimmer Biomet Holdings Expects Full Year 2026 Adjusted EPS Range $8.30$8.45, vs. FactSet Est of $8.46 - marketscreener.com
Earnings Flash (ZBH) Zimmer Biomet Holdings, Inc. Reports Q4 Revenue $2.24B, vs. FactSet Est of $2.22B - marketscreener.com
Earnings Flash (ZBH) Zimmer Biomet Holdings, Inc. Posts Q4 Adjusted EPS $2.42 per Share, vs. FactSet Est of $1.79 - marketscreener.com
ZIMMER BIOMET HOLDINGS ($ZBH) Releases Q4 2025 Earnings - Quiver Quantitative
Zimmer Biomet delivers Q4 earnings beat, cautious 2026 outlook By Investing.com - Investing.com UK
Zimmer: Q4 Financial Results Overview - Bitget
Zimmer Biomet delivers Q4 earnings beat, cautious 2026 outlook - Investing.com
Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results - TradingView
Zimmer Biomet Holdings (NYSE:ZBH) Healthcare Scope Within S&P Futures Narratives - Kalkine Media
Zimmer Biomet Set to Announce Q4 Earnings on February 10 - intellectia.ai
Zimmer Biomet Q4 2025 earnings preview - MSN
Zimmer Biomet Holdings Inc Stock (ZBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):